LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Search

Boston Scientific Corp.

Closed

SectorHealthcare

52.65 -1.74

Overview

Share price change

24h

Current

Min

52.51

Max

54.33

Key metrics

By Trading Economics

Income

669M

1.3B

Sales

-83M

5.2B

P/E

Sector Avg

22.331

51.415

EPS

0.8

Profit margin

25.774

Employees

59,000

EBITDA

116M

1.1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+66.42% upside

Dividends

By Dow Jones

Next Earnings

29 lip 2026

Market Stats

By TradingEconomics

Market Cap

-11B

79B

Previous open

54.39

Previous close

52.65

News Sentiment

By Acuity

24%

76%

42 / 345 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Boston Scientific Corp. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

22 kwi 2026, 11:22 UTC

Earnings

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 lut 2026, 16:14 UTC

Earnings
Major Market Movers

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 lut 2026, 12:13 UTC

Earnings

Boston Scientific Sees More Growth after Earnings, Sales Rise

6 maj 2026, 20:15 UTC

Earnings

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6 maj 2026, 20:07 UTC

Earnings

Penumbra 1Q Rev $374.8M >PEN

6 maj 2026, 20:07 UTC

Earnings

Penumbra 1Q EPS 82c >PEN

22 kwi 2026, 11:07 UTC

Earnings

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 kwi 2026, 10:32 UTC

Earnings

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 kwi 2026, 10:31 UTC

Earnings

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Adj EPS 80c >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific 1Q EPS 90c >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific 1Q Sales $5.2B >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 kwi 2026, 10:30 UTC

Earnings

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 mar 2026, 15:34 UTC

Market Talk

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 lut 2026, 21:41 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 lut 2026, 19:38 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 lut 2026, 17:32 UTC

Earnings

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 lut 2026, 15:30 UTC

Earnings

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 lut 2026, 15:29 UTC

Earnings

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 lut 2026, 14:06 UTC

Earnings

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 lut 2026, 13:58 UTC

Earnings

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 lut 2026, 13:12 UTC

Earnings

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 lut 2026, 11:32 UTC

Earnings

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 lut 2026, 11:31 UTC

Earnings

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 lut 2026, 11:30 UTC

Earnings

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 lut 2026, 11:30 UTC

Earnings

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 lut 2026, 11:30 UTC

Earnings

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

4 lut 2026, 11:30 UTC

Earnings

Boston Scientific 4Q Adj EPS 80c >BSX

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

66.42% upside

12 Months Forecast

Average 89.12 USD  66.42%

High 118 USD

Low 71 USD

Based on 27 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

27 ratings

26

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

102.95 / 104.93Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

42 / 345 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat